Amgen to appeal rejection of bid to block Novartis biosimilar drug
SAN FRANCISCO (Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients, according to a court filing on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Judge rejects Amgen bid to stop biosimilar drug
A federal judge has denied Amgen’s Inc.’s request to temporarily halt the sale of Novartis AG’s biosimilar cancer drug recently approved by the Food and Drug Administration.
Earlier this month, the FDA approved Zarxio, Novartis’ version of Amgen’s Neupogen cancer drug, the first time the agency has approved a biosimilar drug in the U.S. The approval clears the way for various drugmakers to pursue the manufacture of biosimilar medicines, which can cost 20 to 30 percent less than the original… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 20, 2015 Category: Biotechnology Source Type: news
Judge rejects Amgen bid to stop biosimilar drug
A federal judge has denied Amgen’s Inc.’s request to temporarily halt the sale of Novartis AG’s biosimilar cancer drug recently approved by the Food and Drug Administration.
Earlier this month, the FDA approved Zarxio, Novartis’ version of Amgen’s Neupogen cancer drug, the first time the agency has approved a biosimilar drug in the U.S. The approval clears the way for various drugmakers to pursue the manufacture of biosimilar medicines, which can cost 20 to 30 percent less than the original… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 20, 2015 Category: Pharmaceuticals Source Type: news
U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen
NEW YORK (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Zarxio (Filgrastim-sndz Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 12, 2015 Category: Drugs & Pharmacology Source Type: news
7 Bay Area drugs that face competition from cheaper biotech 'generics'
Call them biosimilars, copycats, generics or follow-on biologics, but the age of cheaper versions of biotech drugs is on us.
Just last week, the Food and Drug Administration OK'd Zarxio — the first so-called biosimilar to win FDA approval— from Novartis AG (NYSE: NVS). Zarxio is a version of the Amgen Inc. (NASDAQ: AMGN) drug Neupogen, which increases infection-fighting white blood cell production in chemotherapy patients.
See our 'generics' slideshow. >>>>
At stake are tens of billions of… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 9, 2015 Category: American Health Authors: Ron Leuty Source Type: news
Novartis's Sandoz receives FDA approval for biosimilar Zarxio
Novartis subsidiary Sandoz has received approval from the US Food and Drug Administration (FDA) for its Zarxio (filgrastim-sndz) for all indications included in the reference product's label. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 9, 2015 Category: Pharmaceuticals Source Type: news
FDA Approves First Biosimilar Product (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA has approved the first biosimilar product in the U.S. — filgrastim-sndz (marketed as Zarxio).A biosimilar is a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 9, 2015 Category: Primary Care Source Type: news
First Copycat Biotech Drug Spurs $250B Obamacare Savings
The first U.S. approval of the “generic” biologic prescription version of the widely prescribed anti-infective cancer medicine Neupogen officially opens the door to a new era in cheaper drugs that could save the U.S. health care system tens of billions of dollars a year. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 7, 2015 Category: Pharmaceuticals Authors: Bruce Japsen Source Type: news
First Biosimilar, a Filgrastim Copycat, Is Approved
(MedPage Today) -- Zarxio will compete against Amgen's Neupogen, but price impact still unclear. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 6, 2015 Category: American Health Source Type: news
FDA Approves First US Biosimilar; Hold Your Breath On Cost Savings
The long-anticipated approval of the first biosimilar drug ? a sort of generic biotechnology drug ? occurred this morning. The FDA approved Sandoz's version of the white blood cell growth hormone, filgrastim, the analog of Amgen's Neupogen. But after all of this effort, will it really be less expensive? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 6, 2015 Category: Pharmaceuticals Authors: David Kroll Source Type: news
First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)
The first biosimilar product approved in the United States is filgrastim-sndz (Zarxio, Sandoz/Novartis), which was found to be similar to Amgen's Neupogen. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first biosimilar product Zarxio
The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the U.S. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news
Biosimilars: More Treatment Options Are on the Way
The Food and Drug Administration (FDA) is approving Zarxio (filgrastim-sndz), the first biosimilar product (or biosimilar), and expects to approve others in the months ahead. What are biosimilars? How will they affect patient treatment? (Source: FDA Consumer Updates)
Source: FDA Consumer Updates - March 6, 2015 Category: Consumer Health News Source Type: news
Amgen Urges Court to Block Novartis Neupogen Biosimilar Launch
Amgen Inc. is seeking a preliminary injunction against Sandoz, a subsidiary of Novartis AG, over its application for the biosimilar version of Amgen’s blockbuster drug, Neupogen. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 10, 2015 Category: Pharmaceuticals Source Type: news
